

Quarterly Activity Report and Appendix 4C

Doctor Care Anywhere Group plc (ASX:DOC, “Doctor Care Anywhere” or “the Company”) is pleased to provide an update on trading and corporate activity for the quarter ended 31 March 2026 (“Q1 2026”)¹.

Executive Summary

- **Renewed Consistent Consultation Growth:** For the first quarter of 2026, consultation volumes increased 8.4% quarter-on-quarter, and 2.0% on prior corresponding period.
- **Growth Acceleration Initiatives:** The digital exercise programme across physio services and the skin cancer pathway have now been successfully launched. Early feedback and initial outcomes are encouraging, demonstrating clear value for both clients and patients. In addition, health assessment pilots have been launched internally, with plans to roll these out externally in H2 26.
- **Sustained Strong Positive Cashflow:** £0.6m (A\$1.2m) net operating and investing cash inflow in Q1 2026, compared with a £1.6m (A\$3.3m) cash outflow in the prior corresponding period. This represents the fourth consecutive quarter of positive cash generation.
- **Cash Position:** £7.0m (A\$13.5m) cash on hand at 31 March 2026 versus £2.8m at 31 March 2025, supporting continued investment in business growth.
- **Guidance Reaffirmed:** management reiterates its medium-term targets, including revenue doubling over 3-5 years and a 15% EBITDA margin, subject to the assumptions, risks and qualifications set out in this announcement.

Operational Performance – KPIs

	Actual	% increase / (decrease) on	% increase / (decrease) on
	Q1 2026 000's	Q1 2025 (PcP)	Q4 2025 (QoQ)
Activated Lives ² at Period End	1,304.8	6.4%	2.3%
Consultations ³ in Period	177.3	2.0%	8.4%
Repeat Patients ⁴ in Period	131.6	7.6%	4.6%

¹ This Quarterly Activity Report and Appendix 4C is prepared in GBP in accordance with International Financial Reporting Standards in conformity with the requirements of the Companies Act 2006 (UK) and is unaudited. Figures expressed in Australian Dollars (“A\$”) have been converted from British Pounds Sterling at an exchange rate of AUD:GBP 1:0.52 for Q1 2026, 1:0.50 for Q4 2025 and 1:0.48 for Q1 2025.


² **Activated Lives** represents the total number of people who “sign up” for DOC’s service and enter their personal details.

³ **Consultations** is the number of consultations delivered to patients over the period by a Clinician.

⁴ **Repeat Patients** represents the number of consultations completed by patients who had previously completed an appointment.

⁵ **Secondary Care Journeys** is the number of secondary care journeys completed by patients over the period following a referral from an initial Clinical consultation on the DCA platform.

Consultations by Quarter (000's)



*Follow on appointments relate to DCA's secondary care pathway⁵.

Activated Lives reached 1.3 million, up 6.4% on the prior corresponding period and 2.3% quarter on quarter.

- Consultations grew 2.0% on the prior corresponding period and 8.4% quarter on quarter, supported by the introduction of Mental Health Practitioners and Physiotherapists and enhancements to the booking journey that reduced time to book.
- Repeat patients represented 75% of consultations, in line with the prior quarter and up 3 percentage points year on year.

Cash Flow and Financial Performance

Cash movements	Q1 2026 £000	Q4 2025 £000	% increase /(decrease) QoQ	Q1 2025 £000	% increase /(decrease) versus PcP
Receipts from customers	9,200	9,731	(5.5%)	8,307	10.7%
R&D/Intellectual property costs	(1,409)	(1,382)	1.9%	(1,345)	4.8%
Operating costs	(4,403)	(4,351)	1.2%	(4,304)	2.3%
Other/Non-operating staff costs	(1,700)	(1,546)	10.0%	(2,520)	(32.5%)
Other administrative costs	(1,170)	(1,423)	(17.8%)	(2,016)	(42.0%)
Other cash inflows	65	223	(70.9%)	414	(84.4%)
Total operating and investing inflows/(outflows)	583	1,252	(53.5%)	(1,464)	139.8%
Financing cash flows	(175)	(103)	(68.9%)	(101)	(72.9%)
Exchange gain/(loss)	1	(2)	156.2%	(1)	200.7%
Net cash flow	409	1,147	(64.4%)	(1,566)	126.1%

Net cash inflow of £0.4m (A\$0.8m) marked the fourth consecutive quarter of positive cash generation, compared with a cash outflow in the prior corresponding period.

- Prior corresponding period improvement driven by higher receipts, reduced non operating staff costs, other administrative costs and productivity gains.
- The quarter-on-quarter decrease primarily reflects lower receipts from customers due to timing, an increase in other/non-operating staff costs, and lower other cash inflows following receipt of the annual R&D claim in Q4 2025.
- Non-operating staff costs decreased versus the prior corresponding period due to restructuring costs incurred in Q1 2025. The quarter-on-quarter increase reflects higher consultant costs and new staff hires.
- Other administrative costs decreased versus the prior corresponding period, primarily because annual insurance invoices are being spread evenly across 2026, compared with a full annual payment made in Q1 2025. The quarter-on-quarter decrease reflects supplier charge settlements in Q4 2025 relating to earlier periods.

The company ended Q1 26 with £7.0m (A\$13.5m) in cash as it continues to strengthen its balance sheet. It is actively investing in projects to differentiate its offer in the market and to grow and diversify its customer base.

Activities since previous market update

An update is provided on key operational and financial matters:

Product Expansion

- Core virtual consultation pathway improvements have continued, enhancing the overall patient experience and increasing conversion. The prescription fulfilment journey with the Company's strategic pharmacy partner has now launched, providing patients with greater choice and flexibility.

- Clinical pathways have transitioned from pilot to launch. Early feedback and initial outcomes have been encouraging.
- The digital exercise programme is now accessible on prescription from physiotherapists. The Skin Cancer pathway has achieved a discharge rate of more than 60%, with results available within two days. The Company intends to continue developing this pathway for direct-to-consumer customers and is evaluating a future extension into general dermatology.
- Product development has focused on a new user journey for direct-to-consumer users, who will be provided with clinician availability prior to booking. Another key product focus has been the internal launch of Health Assessments. This product is in pilot phase, with a planned external launch in H2 2026. Internal efficiency projects have also been developed and launched, including ambient AI scribe and AI patient verification.

Operating model transformation

Following the transformation undertaken in H1 25, the focus is now on converting efficiencies into improved profitability and growth momentum.

- Streamlined operations and cost reductions are supporting service delivery, client outcomes and business profitability, while freeing up resources for growth. The Company continues to identify further opportunities to improve operating efficiency.

Medium Term Management Guidance

As presented at the AGM on 30 April 2025, and subject to the assumptions, risks and qualifications described in this announcement:

- Revenue target: £76m (A\$156m) within 3–5 years, doubling from £38m (A\$78m) in 2024.
- Implied CAGR: over 12%.
- EBITDA margin target: 15%

Other

As required by ASX Listing Rule 4.7C.3, the Company discloses that payments to related parties in the period totalled £0.14 million, representing payment of Director Fees to Executive and Non-Executive Directors (including pension and payroll tax payments).

- This update should be read as a whole. It contains forward-looking statements, including in relation to guidance, strategy and future performance. Those statements are not a prediction or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control, which may cause actual results to differ materially from those expressed or implied. Investors should not place undue reliance on forward-looking statements. Except as required by law or the ASX Listing Rules, the Company undertakes no obligation to update those statements.
- This announcement is for information purposes only and does not constitute financial product or investment advice, or an offer or invitation to subscribe for or acquire securities.

Corporate Overview

- 366,741,846 shares/CDIs on issue
- Market capitalisation of A\$55.01m based on the closing price on the date of release
- £7.0m (A\$13.5m) cash at 31 March 2026
- £10.6m (A\$20.4m) in face value of debt under the convertible loan at 31 Mar 2026, which matures on 31 December 2027 and carries zero coupon (interest rate).

- ENDS -

This ASX announcement has been authorised for release by the Board of Directors.

Engage with the Doctor Care Anywhere management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: <https://investors.doctorcareanywhere.com/announcements>

Subscribe to our news alert service: <https://investors.doctorcareanywhere.com/s/db4283>

About Doctor Care Anywhere:

Doctor Care Anywhere Group plc is a leading UK provider of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally enabled telehealth services on its proprietary platform. It is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Doctor Care Anywhere Group plc

ARBN

645 163 873

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows		Current quarter £'000	Year to date (3 months) £'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	9,200	9,200
1.2	Payments for		
	(a) research and development	(728)	(728)
	(b) product manufacturing and operating costs	(4,403)	(4,403)
	(c) advertising and marketing	(99)	(99)
	(d) leased assets	-	-
	(e) staff costs	(1,700)	(1,700)
	(f) administration and corporate costs	(1,066)	(1,066)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	11	11
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	55	55
1.9	Net cash from / (used in) operating activities	1,270	1,270
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(6)	(6)
	(d) investments	-	-
	(e) intellectual property	(681)	(681)
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter £'000	Year to date (3 months) £'000
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	(687)	(687)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(175)	(175)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(175)	(175)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	6,576	6,576
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,270	1,270
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(687)	(687)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(175)	(175)
4.5	Effect of movement in exchange rates on cash held	1	1
4.6	Cash and cash equivalents at end of period	6,985	6,985

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter £'000	Previous quarter £'000
5.1	Bank balances	6,985	6,576
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	6,985	6,576

6.	Payments to related parties of the entity and their associates	Current quarter £'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	142
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end £'000	Amount drawn at quarter end £'000
7.1	Loan facilities	10,610	10,610
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	10,610
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. The loan facility is as announced by the Company on 12 January 2024: https://wcsecure.weblink.com.au/pdf/DOC/02762058.pdf The Convertible Notes bear no interest and may be converted into CDIs by the Convertible Noteholders at any time (provided more than 60 days have passed since the holder's previous conversion) at an issue price of £0.0459 (equivalent to A\$0.0875, based on the exchange rate on 8 December 2023, being a premium of 94% to the closing price of the Company's CDIs on the ASX of A\$0.045 on 11 December). Doctor Care Anywhere may redeem all outstanding Convertible Notes in full on or after 1 January 2026 by repaying the outstanding principal.		

8.	Estimated cash available for future operating activities	£'000
8.1	Net cash from / (used in) operating activities (item 1.9)	1,270
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,985
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	6,985
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer:	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 April 2026

Authorised by: Board of Directors